Smart science to improve lives™
Genetic research and Biotech science


Our Purpose - Smart science to improve lives™ - helps us to identify the right expertise and technologies to drive strategic growth. These acquisitions and investments deliver product development opportunities and continue to enhance our abilities in  R&D and commercialisation.

Filter by

Croda expands Iberchems fragrances offering with the acquisition of Parfex

Croda has acquired a controlling majority 95.6% of Parfex’s outstanding shares, comprising the founding shareholders and certain minority investors.

Read more

Acquisition of Alban Muller

The acquisition expands Croda’s portfolio of sustainable active ingredients for customers in personal care markets.

Read more
Female Perfumer in laboratory

Acquisition of Iberchem expands reach into high growth fragrances market

Acquiring the entire issued share capital of Fragrance Spanish Topco, S.L., trading as Iberchem (“the acquisition”), a leading global fragrances and flavours (“F&F”) company.

Read more

Strengthening Life Sciences with the acquisition of Avanti Polar Lipids

A leader in drug delivery systems for next generation pharmaceuticals, the acquisition more than doubles Croda’s research and development (R&D) capability in drug delivery.

Read more

Strategic investment Entekno Materials

A new Smart Partnership focused on the development of a new particle technology that will deliver superior protection benefits to the sun care and personal care markets.

Read more
Croda employee in lab denmark

Acquisition of global vaccine adjuvant specialist

Vaccine adjuvants are a natural extension to Croda’s market leading, high-purity excipient delivery systems in its Health Care business., these adjuvants represent a niche, high-growth market.

Read more
Female Perfumer in laboratory

Case study: New frontiers in fragrance and flavours - Iberchem, Croda - sustainability, ethics and anti-corruption

Croda acquired international fragrances and flavours company Iberchem in 2020, the largest acquisition in our history and a major move into a market strongly aligned with our business. 

Described as being ‘at the crossroads of science and creativity’, Iberchem brought fragrances into our portfolio, enabling us to create a one-stop-shop for our Personal Care and Home Care customers. As sensory considerations become more important to consumers, fragrances are reported as a primary purchase driver in personal care and household products. They are also a known emotional trigger, with the power to boost wellbeing. 

Our drive to advance the sustainability of practices in the flavours and fragrances sector is shared by our colleagues at Iberchem. For example, 100% of the water used by Iberchem’s production plant in Murcia is recycled by an Authorised Waste Management Company. A solar photovoltaic system was also installed in 2020 that will avoid the annual emission of more than 171 tonnes of CO2 annually.

Our drive to integrate our acquired businesses into our wider ethics and compliance programme is also shared by our colleagues at Iberchem. For example, Iberchem has hired a dedicated compliance officer to oversee the integration of Iberchem into Croda’s wider ethics and anti-corruption programme and has adopted Croda’s Speak Up reporting line.

Read more about our Ethics and Anti-Corruption Programme here

Read more about our Climate Positive Commitment

Case Study: Advancing the efficacy and impact of vaccines - innovation in adjuvants

The acquisition of Biosector in 2018 strengthened our pharmaceutical offering, taking us into the field of vaccine adjuvants. Biosector’s highly experienced team enhanced our existing pharmaceutical offering, bringing world-class innovation and industry-leading manufacturing facilities. 

A leading specialist in this field, our adjuvant technologies are now advancing the efficacy and impact of vaccines to target diseases in well-known areas, such as COVID-19 and conjugate pneumococcal vaccines, alongside developments in more difficult areas such as HIV/AIDS, malaria, hepatitis B and tuberculosis. Our adjuvant pipeline includes vaccines for diseases highlighted by the World Health Organisation (WHO) as key to achieving the United Nations’ Sustainable Development Goal 3 for Good Health and Wellbeing. Advancing our ability to contribute to WHO-listed pipeline vaccines directly contributes to our ambition to become People Positive by 2030.
Read more about our People Positive Commitment